Harnessing transcriptomics and immune cell biology to predict response to checkpoint blockade

Akshay J. Patel
DOI: https://doi.org/10.21037/tcr-24-1322
2024-11-02
Translational Cancer Research
Abstract:Akshay J. Patel 1,2 1 Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; 2 Department of Thoracic Surgery, Guy's Hospital, London, UK Comment on: Hummelink K, Tissier R, Bosch LJW, et al . A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics. Clin Cancer Res 2024;30:814-23. Keywords: Non-small cell lung cancer (NSCLC); effector T cell; programmed death ligand 1 (PD-L1); programmed cell death protein 1 (PD-1); checkpoint blockade Submitted Jul 30, 2024. Accepted for publication Sep 25, 2024. Published online Oct 29, 2024. doi: 10.21037/tcr-24-1322 The landscape of cancer treatment has been significantly transformed by immunotherapy, particularly through the use of programmed cell death protein 1 (PD-1) blockade. However, despite the promise of this approach, it remains effective for only a minority of patients with advanced-stage non-small cell lung cancer (NSCLC). The study by Hummelink et al. , published in Clinical Cancer Research , addresses this critical issue by developing a robust, clinically applicable biomarker to predict nonresponse to PD-1 blockade (1). The study's primary goal was to create a reliable RNA signature reflecting a tumour's PD-1T tumor-infiltrating lymphocyte (TIL) status. PD-1T TILs are a dysfunctional yet tumor-reactive subset of T cells whose presence correlates with a poor response to PD-1 blockade. The researchers aimed to translate the detection of these TILs into a routine clinical diagnostic setting using the NanoString nCounter platform. Baseline tumor samples from 41 patients treated with nivolumab were analysed to develop the predictive gene signature. This training cohort was followed by independent validation in a second cohort of 42 patients. The study's primary outcome was disease control at 12 months (DC12m), with secondary outcomes including progression-free survival (PFS) and overall survival (OS). The study successfully identified a 12-gene RNA signature ( STAT1 , OAS1 , TAP1 , HEY1 , CXCL13 , IFIT2 , IL6 , TDO2 , CD6 , CTLA4 , CD274 , LAG3) that could distinguish between PD-1T immunohistochemistry (IHC)-high tumors from patients with DC12m and PD-1T IHC-low tumors from those with progressive disease (PD). In the validation cohort, the signature correctly classified all 6 patients with DC12m and 23 out of 36 patients with PD, achieving a negative predictive value (NPV) of 100% and a positive predictive value (PPV) of 32%. The RNA signature's high sensitivity and NPV were comparable to those obtained through digital IHC quantification of PD-1T TIL. The study's findings have significant implications for clinical practice. The PD-1T mRNA signature offers a streamlined, less technically demanding alternative to IHC quantification, facilitating its integration into routine diagnostics. This advancement means that clinicians can more accurately identify patients unlikely to benefit from PD-1 blockade, thereby sparing them from ineffective treatments and associated adverse effects. While the study presents promising results, several limitations warrant consideration. The relatively small sample size, especially in the validation cohort, limits the generalizability of the findings. Larger studies are needed to confirm the RNA signature's predictive power across diverse patient populations. The cohorts used in the study were specific to patients treated with nivolumab. It remains to be seen if the RNA signature will be equally predictive for patients treated with other PD-1 inhibitors or combination therapies. Although the NanoString platform simplifies RNA signature analysis compared to traditional methods, integrating this technology into all clinical settings may still present logistical and technical challenges, particularly in resource-limited environments. While the signature's NPV is impressive, the PPV remains relatively low at 32%. This indicates that while the test is excellent at ruling out non-responders, it is less effective at positively identifying those who will benefit from PD-1 blockade. The development of a PD-1T mRNA expression signature represents a significant step forward in the precision medicine approach to NSCLC. By enabling routine clinical diagnostics to predict nonresponse to PD-1 blockade, this biomarker paves the way for more personalized and effective treatment strategies. The reality of the situation however is that there is a plethora of data now published looking at multi-omic, orthogonal ways in which to determine response to checkpoint blockade. With the development of artificial intelligence and radiomics platforms, -Abstract Truncated-
oncology
What problem does this paper attempt to address?